KR102394488B1 - Composition Comprising Piperonylic Acid for Hair Loss Prevention or Hair Growth Promotion - Google Patents
Composition Comprising Piperonylic Acid for Hair Loss Prevention or Hair Growth Promotion Download PDFInfo
- Publication number
- KR102394488B1 KR102394488B1 KR1020210164105A KR20210164105A KR102394488B1 KR 102394488 B1 KR102394488 B1 KR 102394488B1 KR 1020210164105 A KR1020210164105 A KR 1020210164105A KR 20210164105 A KR20210164105 A KR 20210164105A KR 102394488 B1 KR102394488 B1 KR 102394488B1
- Authority
- KR
- South Korea
- Prior art keywords
- hair
- present
- composition
- hair loss
- growth
- Prior art date
Links
- 230000003779 hair growth Effects 0.000 title claims abstract description 46
- 230000003658 preventing hair loss Effects 0.000 title claims abstract description 37
- VDVJGIYXDVPQLP-UHFFFAOYSA-N piperonylic acid Chemical compound OC(=O)C1=CC=C2OCOC2=C1 VDVJGIYXDVPQLP-UHFFFAOYSA-N 0.000 title claims abstract description 25
- 239000000203 mixture Substances 0.000 title claims description 68
- 201000004384 Alopecia Diseases 0.000 claims abstract description 77
- 239000002537 cosmetic Substances 0.000 claims abstract description 43
- 230000001737 promoting effect Effects 0.000 claims abstract description 43
- 230000000694 effects Effects 0.000 claims abstract description 31
- 201000002996 androgenic alopecia Diseases 0.000 claims abstract description 29
- 208000024891 symptom Diseases 0.000 claims abstract description 22
- 235000013305 food Nutrition 0.000 claims abstract description 12
- 229930014626 natural product Natural products 0.000 claims abstract description 6
- 210000004209 hair Anatomy 0.000 claims description 127
- 239000002253 acid Substances 0.000 claims description 59
- 229960005235 piperonyl butoxide Drugs 0.000 claims description 56
- 125000004591 piperonyl group Chemical group C(C1=CC=2OCOC2C=C1)* 0.000 claims description 56
- 230000002500 effect on skin Effects 0.000 claims description 29
- 239000006071 cream Substances 0.000 claims description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims description 14
- 230000035755 proliferation Effects 0.000 claims description 13
- 230000001965 increasing effect Effects 0.000 claims description 12
- 239000003795 chemical substances by application Substances 0.000 claims description 11
- 235000016709 nutrition Nutrition 0.000 claims description 11
- 230000035764 nutrition Effects 0.000 claims description 10
- 239000006210 lotion Substances 0.000 claims description 9
- 238000009472 formulation Methods 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 7
- 239000000443 aerosol Substances 0.000 claims description 6
- 230000002708 enhancing effect Effects 0.000 claims description 6
- 239000003921 oil Substances 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- 239000000654 additive Substances 0.000 claims description 5
- 230000003741 hair volume Effects 0.000 claims description 5
- 239000003755 preservative agent Substances 0.000 claims description 5
- 230000002335 preservative effect Effects 0.000 claims description 5
- 238000005728 strengthening Methods 0.000 claims description 5
- 230000003646 hair health Effects 0.000 claims description 4
- 230000006872 improvement Effects 0.000 claims description 4
- 230000001256 tonic effect Effects 0.000 claims description 4
- 241000195940 Bryophyta Species 0.000 claims description 3
- 239000007844 bleaching agent Substances 0.000 claims description 3
- 239000006260 foam Substances 0.000 claims description 3
- 239000000118 hair dye Substances 0.000 claims description 3
- 239000008266 hair spray Substances 0.000 claims description 3
- 239000004922 lacquer Substances 0.000 claims description 3
- 235000011929 mousse Nutrition 0.000 claims description 3
- 239000002674 ointment Substances 0.000 claims description 3
- 239000002453 shampoo Substances 0.000 claims description 3
- 239000000344 soap Substances 0.000 claims description 3
- 230000000996 additive effect Effects 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 206010068168 androgenetic alopecia Diseases 0.000 abstract description 20
- 239000003814 drug Substances 0.000 abstract description 11
- 229940079593 drug Drugs 0.000 abstract description 8
- 239000004615 ingredient Substances 0.000 abstract description 8
- 230000003676 hair loss Effects 0.000 description 45
- 208000024963 hair loss Diseases 0.000 description 43
- 210000004027 cell Anatomy 0.000 description 34
- 210000003491 skin Anatomy 0.000 description 13
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- 210000002768 hair cell Anatomy 0.000 description 11
- 230000004663 cell proliferation Effects 0.000 description 9
- 238000012360 testing method Methods 0.000 description 8
- 210000003780 hair follicle Anatomy 0.000 description 6
- 230000036541 health Effects 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 231100000360 alopecia Toxicity 0.000 description 5
- 230000010261 cell growth Effects 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- -1 patches Substances 0.000 description 5
- 210000004761 scalp Anatomy 0.000 description 5
- 102000003910 Cyclin D Human genes 0.000 description 4
- 108090000259 Cyclin D Proteins 0.000 description 4
- 239000000499 gel Substances 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 102000001301 EGF receptor Human genes 0.000 description 3
- 108060006698 EGF receptor Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 235000005811 Viola adunca Nutrition 0.000 description 3
- 240000009038 Viola odorata Species 0.000 description 3
- 235000013487 Viola odorata Nutrition 0.000 description 3
- 235000002254 Viola papilionacea Nutrition 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 230000014509 gene expression Effects 0.000 description 3
- 230000003752 improving hair Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 239000012679 serum free medium Substances 0.000 description 3
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 2
- FTZIQBGFCYJWKA-UHFFFAOYSA-N 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium Chemical compound S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 FTZIQBGFCYJWKA-UHFFFAOYSA-N 0.000 description 2
- 108010066551 Cholestenone 5 alpha-Reductase Proteins 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 201000009495 Hypotrichosis Diseases 0.000 description 2
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 description 2
- 239000004909 Moisturizer Substances 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 208000004631 alopecia areata Diseases 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000001747 exhibiting effect Effects 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 229960004039 finasteride Drugs 0.000 description 2
- DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 2
- 235000013376 functional food Nutrition 0.000 description 2
- 210000000442 hair follicle cell Anatomy 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 229960003632 minoxidil Drugs 0.000 description 2
- 230000001333 moisturizer Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 1
- 229940015975 1,2-hexanediol Drugs 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 206010059245 Angiopathy Diseases 0.000 description 1
- 206010003694 Atrophy Diseases 0.000 description 1
- 208000001840 Dandruff Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000017701 Endocrine disease Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 208000034826 Genetic Predisposition to Disease Diseases 0.000 description 1
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- 235000019510 Long pepper Nutrition 0.000 description 1
- 206010026749 Mania Diseases 0.000 description 1
- 240000003455 Piper longum Species 0.000 description 1
- 244000203593 Piper nigrum Species 0.000 description 1
- 235000008184 Piper nigrum Nutrition 0.000 description 1
- 241000758706 Piperaceae Species 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 201000001880 Sexual dysfunction Diseases 0.000 description 1
- 206010059516 Skin toxicity Diseases 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 208000002474 Tinea Diseases 0.000 description 1
- 241000893966 Trichophyton verrucosum Species 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010306 acid treatment Methods 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 229940030486 androgens Drugs 0.000 description 1
- 229960003473 androstanolone Drugs 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000001164 bioregulatory effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 230000003778 catagen phase Effects 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 208000034557 congenital alopecia Diseases 0.000 description 1
- 239000000490 cosmetic additive Substances 0.000 description 1
- 239000003581 cosmetic carrier Substances 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 239000002781 deodorant agent Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 208000030172 endocrine system disease Diseases 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 210000000720 eyelash Anatomy 0.000 description 1
- 230000003645 female-pattern hair loss Effects 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- FHKSXSQHXQEMOK-UHFFFAOYSA-N hexane-1,2-diol Chemical compound CCCCC(O)CO FHKSXSQHXQEMOK-UHFFFAOYSA-N 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000016507 interphase Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 230000003780 keratinization Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 230000003273 male-pattern hair loss Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 239000013028 medium composition Substances 0.000 description 1
- 231100000324 minimal toxicity Toxicity 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- 230000001272 neurogenic effect Effects 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- BMXXSXQVMCXGJM-UHFFFAOYSA-N pipamperone dihydrochloride Chemical compound [Cl-].[Cl-].C1CC(C(=O)N)([NH+]2CCCCC2)CC[NH+]1CCCC(=O)C1=CC=C(F)C=C1 BMXXSXQVMCXGJM-UHFFFAOYSA-N 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000037390 scarring Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 231100000872 sexual dysfunction Toxicity 0.000 description 1
- 230000037384 skin absorption Effects 0.000 description 1
- 231100000274 skin absorption Toxicity 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 230000036560 skin regeneration Effects 0.000 description 1
- 231100000438 skin toxicity Toxicity 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000003797 telogen phase Effects 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 208000019553 vascular disease Diseases 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q5/00—Preparations for care of the hair
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/30—Other Organic compounds
Abstract
Description
본 발명은 피페로닐산의 탈모 방지 또는 발모 촉진 용도에 관한 것이다.The present invention relates to the use of piperonyl acid for preventing hair loss or promoting hair growth.
탈모는 정상적으로 모발이 존재해야 할 부위에 모발이 부족한 상태를 말하며, 불규칙한 생활습관과 스트레스, 남성호르몬, 유전 및 영양 불균형 등 선천적인 요인과 후천적인 요인이 복합적으로 연관되어 발병하는 것으로 알려져 있다. 탈모가 진행되면서 연모화 현상으로 모발이 가늘고 힘이 없어지며 성장기가 단축되어 휴지기 또는 퇴행기에서 모발의 탈락이 형성되고 모낭의 위축으로 모낭에 영양공급이 안되어 모낭의 기능을 상실하는 등의 현상을 보이게 된다. Hair loss refers to a condition in which there is insufficient hair in the area where hair should normally exist, and it is known that innate and acquired factors such as irregular lifestyle, stress, male hormones, genetic and nutritional imbalances are complexly related. As hair loss progresses, hair follicles become thin and weak due to the phenomenon of vellus hair growth, and the growth phase is shortened, resulting in hair loss in the resting or regression phase, and the atrophy of the hair follicles causes the hair follicles to lose their function. do.
탈모는 의학적인 문제 외에도 피부 미용상 문제를 일으킬 수 있기 때문에 탈모를 방지하거나 발모를 촉진할 수 있는 성분이 의약품 및 화장품 등으로 개발되어 왔다.Since hair loss can cause skin cosmetic problems in addition to medical problems, ingredients that can prevent hair loss or promote hair growth have been developed as pharmaceuticals and cosmetics.
현재 탈모 방지 또는 발모 촉진을 위해 사용되는 대표적인 성분은 피부에 도포하는 미녹시딜과 경구 투여하는 피나스테리드 등이 있으며, 미국 FDA에서 탈모 치료 의약품으로 허가되어 있어 탈모 치료를 위한 약물로 널리 사용되고 있다. 그러나, 미녹시딜과 피나스테리드는 우울증 및 성기능 장애 등에 대한 부작용이 있고, 장기간 복용을 하여야 하며 치료 중단 시 다시 탈모가 시작되는 부작용 및 독성 등이 보고된 바 있다. 때문에 장기간 투여해도 독성이 적고 부작용이 최소화된 천연물 유래 성분을 활용한 탈모 방지제 또는 발모제에 대한 관심이 증가되고 있다.Currently, representative ingredients used for preventing hair loss or promoting hair growth include minoxidil applied to the skin and finasteride administered orally. However, minoxidil and finasteride have side effects for depression and sexual dysfunction, etc., have to be taken for a long time, and side effects and toxicity that start hair loss again when treatment is stopped have been reported. Therefore, interest in hair loss prevention agents or hair growth agents using natural ingredients with minimal toxicity and minimal side effects even after long-term administration is increasing.
피페로닐산(piperonylic acid)은 다양한 식물에서 분리된 천연물 유래 성분이다. 대한민국 공개특허 제10-2019-0014340호는 피페로닐산이 세포 수준에서 EGF(epidermal growth factor) 수용체를 활성화시키고 일부 피부 세포의 증식을 촉진한다는 결과를 보고한다. 그러나, 상기 문헌은 오직 피부 재생과 관련한 세포실험 결과를 구체적으로 기재하고 있으며, 탈모 방지 또는 발모 촉진과 관련한 효과는 전혀 개시하고 있지 않다.Piperonylic acid is a component derived from natural products isolated from various plants. Korean Patent Application Laid-Open No. 10-2019-0014340 reports that piperonyl acid activates epidermal growth factor (EGF) receptors at the cellular level and promotes the proliferation of some skin cells. However, the above document only specifically describes the results of cell experiments related to skin regeneration, and does not disclose any effects related to preventing hair loss or promoting hair growth.
한편, 문헌[Alexandrescu, Doru T., C. Lisa Kauffman, and Constantin A. Dasanu. Dermatology online journal 15.3 (2009).] 등은 EGF 수용체 억제제가 속눈썹과 두피 모발의 조기 성숙(말단 분화)와 같은 모발 성장 효과를 나타낸다고 보고하고 있다. 상기 문헌은 EGF 수용체 활성화와 반대되는 EGF 수용체 억제제의 탈모 방지 또는 발모 촉진 효과에 관한 문헌이며, 피페로닐산에 대해서는 전혀 개시하고 있지 않다.On the other hand, Alexandrescu, Doru T., C. Lisa Kauffman, and Constantin A. Dasanu. Dermatology online journal 15.3 (2009).] report that EGF receptor inhibitors exhibit hair growth effects such as early maturation (terminal differentiation) of eyelashes and scalp hair. The above document relates to the hair loss prevention or hair growth promoting effect of an EGF receptor inhibitor as opposed to EGF receptor activation, and does not disclose piperonyl acid at all.
이에, 본 발명자는 장기간 투여가 가능하고 부작용이 적은 탈모 방지 또는 발모 촉진제를 개발하기 위해 예의 노력하던 중, 놀랍게도 피페로닐산이 모발 세포뿐 아니라 임상적으로 탈모 방지 또는 발모 촉진 효과를 나타낸다는 점을 확인하고 본 발명을 완성하였다.Accordingly, the present inventors have been making intensive efforts to develop a hair loss prevention or hair growth promoting agent that can be administered for a long period of time and have fewer side effects, and surprisingly, piperonilic acid exhibits an effect of preventing hair loss or promoting hair growth clinically as well as hair cells. Confirmed and completed the present invention.
본 발명의 목적은 피페로닐산의 탈모 방지 또는 발모 촉진 용도를 제공하는 것이다An object of the present invention is to provide a use for preventing hair loss or promoting hair growth of piperonyl acid.
본 발명의 또 다른 목적은 피페로닐산을 포함하는 탈모 방지 또는 발모 촉진용 화장료, 약학 또는 식품 조성물을 제공하는 것이다.Another object of the present invention is to provide a cosmetic, pharmaceutical or food composition for preventing hair loss or promoting hair growth comprising piperonyl acid.
상기 목적을 달성하기 위해, 본 발명자는 피페로닐산이 모발 세포에서, 그리고 사람에서 탈모 방지 또는 발모 촉진 효과를 발휘한다는 점을 구체적으로 확인하고 본 발명을 완성하였다.In order to achieve the above object, the present inventors have completed the present invention by confirming specifically that piperonyl acid exerts an effect of preventing hair loss or promoting hair growth in hair cells and in humans.
일 측면에서, 본 발명은 피페로닐산을 포함하는 탈모 방지 또는 발모 촉진용 화장료 조성물을 제공한다. 상기 피페로닐산은 천연물에서 유래되거나 화학적으로 합성될 수 있다.In one aspect, the present invention provides a cosmetic composition for preventing hair loss or promoting hair growth comprising piperonyl acid. The piperonyl acid may be derived from a natural product or may be chemically synthesized.
상기 화장료 조성물은 모발 굵기 증가, 모발 탄력 강화, 모발 볼륨감 강화 및 모발 수 증가로 구성된 군에서 선택된 1종 이상의 모발 건강 개선 용도를 가질 수 있다. 구체적으로, 상기 화장료 조성물은 안드로겐성 탈모 증상을 완화할 수 있고, 모유두 세포의 증식을 촉진할 수 있다.The cosmetic composition may have one or more uses for improving hair health selected from the group consisting of increasing hair thickness, enhancing hair elasticity, enhancing hair volume, and increasing the number of hairs. Specifically, the cosmetic composition can alleviate androgenic alopecia symptoms, and can promote the proliferation of dermal papilla cells.
본 발명의 화장료 조성물에 포함되는 피페로닐산은 조성물 기준 0.005 중량% 내지 5 중량%일 수 있다. 상기 화장료 조성물은 화장품으로 허용 가능한 1종 이상의 첨가제 또는 담체를 포함할 수 있다. 더욱 구체적으로, 상기 화장료 조성물은 헤어토닉, 헤어컨디셔너, 헤어에센스, 헤어로션, 헤어영양로션, 헤어샴푸, 헤어린스, 헤어트리트먼트, 헤어크림, 헤어영양크림, 헤어모이스처크림, 헤어맛사지크림, 헤어왁스, 헤어 에어로졸, 헤어팩, 헤어영양팩, 헤어비누, 헤어클렌징폼, 머릿기름, 모발건조제, 모발보존처리제, 모발염색제, 모발용 웨이브제, 모발탈색제, 헤어겔, 헤어글레이즈, 헤어드레싱어, 헤어래커, 헤어모이스처라이저, 헤어무스 및 헤어스프레이로 구성된 1종 이상의 제형일 수 있다.The piperonyl acid contained in the cosmetic composition of the present invention may be 0.005 wt% to 5 wt% based on the composition. The cosmetic composition may include one or more cosmetically acceptable additives or carriers. More specifically, the cosmetic composition is a hair tonic, hair conditioner, hair essence, hair lotion, hair nutrition lotion, hair shampoo, hair conditioner, hair treatment, hair cream, hair nutrition cream, hair moisture cream, hair massage cream, hair Wax, hair aerosol, hair pack, hair nutrition pack, hair soap, hair cleansing foam, hair oil, hair dryer, hair preservative, hair dye, hair wave agent, hair bleach, hair gel, hair glaze, hair dresser, hair lacquer, It may be one or more formulations consisting of a hair moisturizer, a hair mousse, and a hair spray.
또 다른 일 측면에서, 본 발명은 피페로닐산을 포함하는 탈모 방지 또는 발모 촉진용 약학 조성물을 제공한다. 일 실시양태에서, 상기 약학 조성물은 에어로졸제, 연고, 액제, 로션제, 패치제, 도포용 분말, 오일, 크림 및 겔로 구성된 군에서 선택된 1종 이상의 피부 외용제일 수 있다.In another aspect, the present invention provides a pharmaceutical composition for preventing hair loss or promoting hair growth comprising piperonyl acid. In one embodiment, the pharmaceutical composition may be one or more external preparations for skin selected from the group consisting of aerosols, ointments, solutions, lotions, patches, powders for application, oils, creams, and gels.
또 다른 일 측면에서, 본 발명은 피페로닐산을 포함하는 탈모 방지 또는 발모 촉진용 식품 조성물을 제공한다.In another aspect, the present invention provides a food composition for preventing hair loss or promoting hair growth comprising piperonyl acid.
본 발명에 따른 피페로닐산의 탈모 방지 또는 발모 촉진용 조성물은 천연물 유래 성분을 유효성분으로 사용하여 안전하고 부작용이 적으며, 안드로겐성 탈모 증상 완화 및 모발 세포 성장 및 증식 효과가 우수하므로 탈모 방지 또는 발모 촉진용 화장품, 의약품, 의약외품 또는 식품 등으로 유용하게 활용가능하다.The composition for preventing hair loss or promoting hair growth of piperonyl acid according to the present invention is safe and has few side effects by using a natural product-derived ingredient as an active ingredient, and has excellent androgenic alopecia symptom relief and hair cell growth and proliferation effects. It can be usefully used as cosmetics, pharmaceuticals, quasi-drugs, or food for promoting hair growth.
도 1은 본 발명에 따른 탈모 방지 또는 발모 촉진용 화장료 조성물 제형의 대표 사진을 나타내고,
도 2는 피페로닐산의 안드로겐성 탈모 유래 모유두세포 성장 및 증식 촉진 효과를 확인한 결과를 나타내고,
도 3은 피페로닐산의 안드로겐성 탈모 유래 모유두세포 처리 시 성장 및 증식 촉진에 관여하는 Cyclin D 단백질 발현 증가를 확인한 결과를 나타내고,
도 4는 피페로닐산의 안드로겐성 탈모 유래 모유두세포 성장 및 증식 촉진 효과를 확인한 결과 나타낸 사진이고,
도 5는 피험자들을 대상으로 피페로닐산의 안드로겐성 탈모 증상의 완화 효과를 확인한 인체적용시험 결과를 나타낸 사진이고,
도 6은 피험자들을 대상으로 피페로닐산의 안드로겐성 탈모 증상의 완화 효과를 확인한 인체적용시험 결과를 나타낸 그래프이다.1 shows a representative photograph of a cosmetic composition formulation for preventing hair loss or promoting hair growth according to the present invention;
Figure 2 shows the results of confirming the effect of piperonyl acid to promote androgenetic hair loss-derived dermal papilla cell growth and proliferation,
3 shows the results of confirming the increase in the expression of Cyclin D protein involved in the promotion of growth and proliferation during androgenetic hair loss-derived dermal papilla cell treatment with piperonyl acid,
4 is a photograph showing the results of confirming the effect of piperonyl acid to promote androgenetic hair loss-derived dermal papilla cell growth and proliferation;
5 is a photograph showing the results of a human application test confirming the alleviation effect of androgenetic alopecia symptoms of piperonyl acid for subjects,
6 is a graph showing the results of a human application test confirming the alleviation effect of androgenetic alopecia symptoms of piperonyl acid for subjects.
본 발명은 피페로닐산을 포함하는 탈모 방지 또는 발모 촉진용 화장료 조성물, 약학 조성물 및 식품 조성물을 제공하며, 각각에 대한 설명을 하기에 상술한다.The present invention provides a cosmetic composition, a pharmaceutical composition and a food composition for preventing hair loss or promoting hair growth containing piperonyl acid, each of which will be described in detail below.
일 측면에서, 본 발명은 피페로닐산을 포함하는 탈모 방지 또는 발모 촉진용 화장료 조성물을 제공한다. 여기서, 피페로닐산(piperonylic acid)은 하기 화학식 1로 표시되는 화합물이다.In one aspect, the present invention provides a cosmetic composition for preventing hair loss or promoting hair growth comprising piperonyl acid. Here, piperonylic acid is a compound represented by the following formula (1).
[화학식 1][Formula 1]
본 발명에서, 피페로닐산은 천연물에서 유래된 것일 수 있다. 예컨대 본 발명의 피페로닐산은 후추과 식물(Piper nigrum L. 또는 Piper longum L.) 추출물에 포함되거나 이로부터 분리된 것일 수 있다. 또는, 본 발명의 피페로닐산은 화학적으로 합성된 것일 수 있다. 본 발명의 피페로닐산은 그 제조방법이 당업계에 공지되어 있으며, 상업적으로 용이하게 입수할 수 있다(CAS No.: 94-53-1).In the present invention, piperonyl acid may be derived from a natural product. For example, the piperonyl acid of the present invention may be contained in or isolated from the extract of the plant Pepper family (Piper nigrum L. or Piper longum L.). Alternatively, the piperonyl acid of the present invention may be chemically synthesized. The method for preparing piperonyl acid of the present invention is known in the art, and it can be easily obtained commercially (CAS No.: 94-53-1).
본 발명에서, 피페로닐산은 유리산 형태의 피페로닐산 외에도 피페로닐산의 화장품으로 허용 가능한 염을 포함한다.In the present invention, piperonylic acid includes cosmetically acceptable salts of piperonylic acid in addition to piperonylic acid in the free acid form.
본 발명에서, 피페로닐산은 탈모 방지 또는 모발 촉진을 위한 유효성분으로 조성물에 포함될 수 있다.In the present invention, piperonyl acid may be included in the composition as an active ingredient for preventing hair loss or promoting hair.
본 발명에서, 용어 “모발”은 각질화된 상피세포로 이루어져 피부 표면으로 나오는 실 모양으로 된 구조물을 지칭하며, 체모와 두발을 모두 포함한다.In the present invention, the term “hair” refers to a thread-like structure made up of keratinized epithelial cells and coming out of the skin surface, and includes both body hair and hair.
본 발명에서, 용어 “탈모”는 피부로부터 모발이 탈락하는 현상 또는 모발이 성기거나 가늘어지는 상태를 지칭하며, 탈모 증상과 혼용되어 사용될 수 있다. 본 발명에서 탈모는 영양장애성 탈모, 내분비장애성 탈모, 혈관장애성 탈모, 장년성 탈모, 결발성 탈모, 원형 탈모, 신경성 탈모, 비강성 탈모, 트리코틸로 마니아, 악성탈모, 여성형 탈모, 남성형 탈모, 안드로겐성 탈모, 휴지기 탈모, 두부 백선, 전두 탈모, 감모증, 유전성 단순 감모증, 전신 탈모약제성 탈모, 기계적 탈모, 외상성 탈모, 압박성 탈모, 생장기 탈모, 매독성 탈모, 지루 탈모, 증후성 탈모, 반흔성 탈모 또는 선천성 탈모를 포함하나 반드시 이에 제한되지 않는다. 본 발명에서 탈모는 발생의 직간접적인 원인을 불문하고 탈모로 분류될 수 있는 모든 증상을 포함하는 의미로서 이해되어야 한다. In the present invention, the term “hair loss” refers to a phenomenon in which hair falls off from the skin or a condition in which hair is sparse or thin, and may be used in combination with a symptom of hair loss. In the present invention, hair loss is dystrophic hair loss, endocrine disorder hair loss, vascular disorder hair loss, senile hair loss, spontaneous hair loss, alopecia areata, neurogenic hair loss, alopecia areata, tricotyl mania, malignant hair loss, female pattern hair loss, male pattern Hair loss, androgenetic alopecia, telogen hair loss, ringworm of the head, frontal alopecia, hypotrichosis, hereditary hypotrichosis, generalized hair loss, pharmaceutical alopecia, mechanical hair loss, traumatic hair loss, pressure hair loss, genital hair loss, syphilitic hair loss, seborrheic hair loss, symptoms including, but not necessarily limited to, hair loss sexually, scarring alopecia, or congenital alopecia. In the present invention, hair loss should be understood as meaning including all symptoms that can be classified as hair loss regardless of the direct or indirect cause of the occurrence.
본 발명에서, 탈모 방지는 탈모와 연관된 하나 이상의 증상의 발생 또는 발병이 억제되거나 지연되는 모든 행위를 의미하며, 반드시 탈모의 완전한 발병 억제에 국한되지 않는다. In the present invention, hair loss prevention refers to any action in which the occurrence or onset of one or more symptoms associated with hair loss is suppressed or delayed, and is not necessarily limited to complete suppression of hair loss.
본 발명에서, 발모 촉진은 모발의 생성 또는 성장에 직간접적으로 기여하는 모든 현상을 의미한다.In the present invention, hair growth promotion refers to any phenomenon that directly or indirectly contributes to the generation or growth of hair.
본 발명의 실시예에서, 피페로닐산이 모유두 세포의 증식을 촉진하는 효과를 가짐을 실험적으로 확인하였다(도 2 내지 도 4). In an embodiment of the present invention, it was experimentally confirmed that piperonyl acid has the effect of promoting the proliferation of dermal papilla cells ( FIGS. 2 to 4 ).
일반적으로 모발의 성장에는 모유두세포, 모모세포 등 다양한 종류의 세포가 상호작용하므로 일부 모발 세포를 대상으로 하는 세포 증식능 실험 외에도 임상적인 탈모 방지 또는 발모 촉진 효과를 확인할 필요가 있다. 이에, 본 발명에서는 피페로닐산을 포함하는 조성물을 안드로겐성 탈모 증상을 겪는 남성을 대상으로 두피에 6 주 또는 12 주 이상 적용할 경우, 탈모 방지 또는 발모 촉진 효과를 발휘한다는 점을 확인하였다(도 5 및 도 6).In general, since various types of cells such as dermal papilla cells and hair cells interact for hair growth, it is necessary to confirm the clinical effect of preventing hair loss or promoting hair growth in addition to the cell proliferation test targeting some hair cells. Therefore, in the present invention, it was confirmed that when the composition containing piperonyl acid was applied to the scalp for 6 weeks or 12 weeks or more for men suffering from androgenic alopecia symptoms, it was confirmed that it exerts an effect of preventing hair loss or promoting hair growth (Fig. 5 and 6).
따라서, 본 발명의 피페로닐산을 포함하는 조성물은 탈모 방지 또는 발모 촉진에 유용하게 활용될 수 있다. Therefore, the composition comprising piperonyl acid of the present invention can be usefully used to prevent hair loss or promote hair growth.
본 발명의 조성물은 모발 건강 개선 효과를 가지며, 구체적으로 모발 굵기 증가, 모발 탄력 강화, 모발 볼륨감 강화 및 모발 수 증가로 구성된 군에서 선택된 1종 이상의 모발 건강 개선 효과를 나타낼 수 있다.The composition of the present invention has a hair health improvement effect, and specifically, may exhibit an effect of improving hair health of at least one selected from the group consisting of an increase in hair thickness, strengthening of hair elasticity, strengthening of hair volume, and increasing the number of hairs.
본 발명의 조성물은 안드로겐성 탈모(androgenic alopecia) 증상을 완화할 수 있다. 본 발명에서, 용어 “안드로겐성 탈모”는 당업계에서 사용되는 것과 같은 의미로 정의된다. 안드로겐성 탈모는 유전적 소인과 남성호르몬인 안드로겐의 작용으로 발생하는 탈모이다. 테스토스테론이 모낭에 도달하면 5α-환원효소에 의해 디하이드로테스토스테론(Dihydrotestosterone; DHT)으로 전환되는데, DHT는 모낭을 위축시키고 모발을 서서히 가늘게 만들어 탈모 증상을 나타내는 것으로 알려져 있다. 안드로겐성 탈모 증상은 남성형 및 여성형 탈모 모두에서 나타날 수 있다.The composition of the present invention can alleviate androgenic alopecia symptoms. In the present invention, the term “androgenic alopecia” is defined as the meaning used in the art. Androgenetic alopecia is a hair loss that occurs due to genetic predisposition and the action of androgens, which are male hormones. When testosterone reaches the hair follicle, it is converted to dihydrotestosterone (DHT) by 5α-reductase. DHT is known to cause hair loss by atrophying the hair follicles and making the hair gradually thin. Androgenetic alopecia symptoms can appear in both male and female pattern alopecia.
본 발명의 화장료 조성물은 모유두(dermal papilla) 세포의 증식을 촉진할 수 있다. 구체적으로, 본 발명의 모유두 세포는 안드로겐성 탈모 증상과 관련된 모유두 세포일 수 있다. 본 발명의 실시예에서, 본 발명의 화장료 조성물이 남성 안드로겐성 탈모 환자 두피의 모낭에서 분리된 모유두 세포의 성장 및 증식 촉진 효과가 있음을 확인하였다(도 2 내지 4). The cosmetic composition of the present invention can promote the proliferation of dermal papilla cells. Specifically, the dermal papilla cells of the present invention may be dermal papilla cells associated with androgenetic alopecia symptoms. In an embodiment of the present invention, it was confirmed that the cosmetic composition of the present invention has an effect of promoting growth and proliferation of dermal papilla cells isolated from the hair follicles of the scalp of male androgenetic alopecia patients (Figs. 2 to 4).
또한, 본 발명의 화장료 조성물은 안드로겐성 탈모 환자의 탈모증을 완화할 수 있다. 구체적으로, 본 발명에서 피험자들을 대상으로 피페로닐산을 포함하는 화장료 조성물을 12주 동안 1일 1회 도포한 결과 안드로겐성 탈모 증상이 완화되고, 모발 수 등이 통계적으로 증가하였음을 확인하였다(도 5 및 도 6).In addition, the cosmetic composition of the present invention can alleviate alopecia in androgenetic alopecia patients. Specifically, as a result of applying the cosmetic composition containing piperonilic acid to subjects in the present invention once a day for 12 weeks, it was confirmed that androgenetic alopecia symptoms were alleviated and the number of hairs increased statistically (Fig. 5 and 6).
본 발명의 화장료 조성물은 단독적으로 탈모 방지 또는 발모 촉진 효과를 발휘할 수 있거나, 피페로닐산의 탈모 방지 또는 발모 촉진 효과를 보조하는 1종 이상의 추가적인 성분을 더 포함할 수 있다. 예컨대, 본 발명의 화장료 조성물은 5α-환원효소 억제 성분, 모근 및 모낭세포 활성 성분, 모낭세포 혈류 증강 성분, 살균 성분, 비듬방지제, 각질 연화제, 청량제, 보습제 등을 더 포함할 수 있으나, 이에 제한되지 않는다. 본 발명의 기술적 사상은 피페로닐산이 단독적으로 탈모 방지 또는 발모 촉진 효과를 나타낸다는 점에 있으므로 본 발명의 화장료 조성물에서 피페로닐산 이외에 포함될 수 있는 1종 이상의 추가적인 성분은 임의적으로 포함되거나 또는 포함되지 않을 수 있다.The cosmetic composition of the present invention may exert the effect of preventing hair loss or promoting hair growth by itself, or may further include one or more additional ingredients that assist the effect of preventing hair loss or promoting hair growth of piperonyl acid. For example, the cosmetic composition of the present invention may further include a 5α-reductase inhibitory component, a hair root and hair follicle cell active component, a hair follicle cell blood flow enhancing component, a sterilizing component, an anti-dandruff agent, a keratin emollient, a refreshing agent, a moisturizing agent, and the like, but is limited thereto. doesn't happen The technical idea of the present invention is that piperonyl acid alone exhibits an effect of preventing hair loss or promoting hair growth, so one or more additional ingredients that may be included in addition to piperonyl acid in the cosmetic composition of the present invention are optionally included or not included. it may not be
본 발명의 피페로닐산을 포함하는 화장료 조성물은 피부나 모발의 기능 약화로 인한 건조함, 갈라짐, 빠짐, 각질화 등을 방지하거나 개선하는 데에 도움을 주는 기능성 화장품 제품으로 활용될 수 있다.The cosmetic composition containing piperonyl acid of the present invention can be used as a functional cosmetic product that helps prevent or improve dryness, cracking, loss, keratinization, etc. due to weakening of skin or hair function.
본 발명에서, 화장료 조성물에 포함되는 피페로닐산은 화장품으로 사용될 때 탈모 방지 또는 발모 촉진 효과를 나타내면서 피부 독성을 나타내지 않는 적절한 함량으로 사용되어야 하며, 본 발명자는 조성물 기준 0.005 중량% 내지 5 중량%가 적정 함량임을 확인하였다(도 5 및 도 6). 보다 바람직하게는, 조성물 기준 0.01 중량% 내지 1.0 중량%의 피페로닐산이 조성물에 포함될 수 있다.In the present invention, piperonyl acid contained in the cosmetic composition should be used in an appropriate amount that does not show skin toxicity while exhibiting an effect of preventing hair loss or promoting hair growth when used as a cosmetic, and the present inventors have found that 0.005 wt% to 5 wt% based on the composition It was confirmed that the content was appropriate ( FIGS. 5 and 6 ). More preferably, 0.01 wt% to 1.0 wt% of piperonilic acid may be included in the composition based on the composition.
본 발명의 화장료 조성물은 피페로닐산 외에 화장품으로 허용 가능한 1종 이상의 첨가제 또는 담체를 포함할 수 있다. The cosmetic composition of the present invention may include one or more cosmetically acceptable additives or carriers in addition to piperonyl acid.
본 발명에서, 화장품으로 허용 가능한 첨가제는 피페로닐산의 물리화학적 특성에 비추어 볼 때 피페로닐산의 기능성을 해치지 않는 첨가제라면 당업계에 알려진 화장품 첨가제, 예컨대 충전제, 결합제, 붕해제, 윤활제, 현탁화제, 용제, 산화방지제, pH 조절제, 습윤제, 감미제 또는 보존제 등을 적절히 혼합하여 사용할 수 있다.In the present invention, cosmetically acceptable additives are cosmetic additives known in the art, such as fillers, binders, disintegrants, lubricants, suspending agents, as long as they do not impair the functionality of piperonyl acid in view of the physicochemical properties of piperonyl acid. , a solvent, an antioxidant, a pH adjuster, a wetting agent, a sweetener or a preservative, etc. may be appropriately mixed and used.
본 발명에서, 화장품으로 허용 가능한 담체는 피페로닐산의 물리화학적 특성에 비추어 볼 때 피페로닐산의 기능성을 해치지 않는 담체라면 당업계에 알려진 화장품 담체, 예컨대 겔화제, 활성제, 보존제, 항산화제, 안정화제, 용해화제, 비타민, 용매, 방향제, 충전제, 차단제, 안료, 흡취제 또는 염료 등 적절히 혼합하여 사용할 수 있다.In the present invention, a cosmetically acceptable carrier is a cosmetic carrier known in the art, such as a gelling agent, an active agent, a preservative, an antioxidant, a stable agent, as long as it does not impair the functionality of piperonyl acid in view of the physicochemical properties of piperonyl acid. An agent, solubilizer, vitamin, solvent, fragrance, filler, blocker, pigment, deodorant, dye, etc. may be appropriately mixed and used.
일 실시양태에서, 인체 피부 도포시 피페로닐산의 탈모방지 또는 발모촉진 기능성을 향상시키고, 피부 안전성을 확보하기 위해 본 발명의 화장료 조성물에 카보머, 알코올 폴리에틸렌 에테르(예컨대, 옥틸도데세스-16), 부틸렌글라이콜, 1,2-헥산디올, 에탄올 또는 이들의 조합과 같은 1종 이상의 첨가제 또는 담체를 더 포함시킬 수 있다(제조예 참조).In one embodiment, carbomer, alcohol polyethylene ether (e.g., octyldodeces-16) is added to the cosmetic composition of the present invention to improve the hair loss prevention or hair growth promoting function of piperonyl acid when applied to human skin and to ensure skin safety One or more additives or carriers such as , butylene glycol, 1,2-hexanediol, ethanol, or a combination thereof may be further included (see Preparation Example).
본 발명의 화장료 조성물은 탈모 방지 또는 발모 촉진을 위해 모발에 적절히 적용될 수 있는 제형으로 제조될 수 있다. 구체적으로, 본 발명의 화장료 조성물은 헤어토닉, 헤어컨디셔너, 헤어에센스, 헤어로션, 헤어영양로션, 헤어샴푸, 헤어린스, 헤어트리트먼트, 헤어크림, 헤어영양크림, 헤어모이스처크림, 헤어맛사지크림, 헤어왁스, 헤어 에어로졸, 헤어팩, 헤어영양팩, 헤어비누, 헤어클렌징폼, 머릿기름, 모발건조제, 모발보존처리제, 모발염색제, 모발용 웨이브제, 모발탈색제, 헤어겔, 헤어글레이즈, 헤어드레싱어, 헤어래커, 헤어모이스처라이저, 헤어무스 및 헤어스프레이로 구성된 1종 이상의 제형으로 제조될 수 있다.The cosmetic composition of the present invention may be prepared in a formulation that can be appropriately applied to hair to prevent hair loss or promote hair growth. Specifically, the cosmetic composition of the present invention is a hair tonic, hair conditioner, hair essence, hair lotion, hair nutrition lotion, hair shampoo, hair conditioner, hair treatment, hair cream, hair nutrition cream, hair moisture cream, hair massage cream, Hair wax, hair aerosol, hair pack, hair nutrition pack, hair soap, hair cleansing foam, hair oil, hair dryer, hair preservative, hair dye, hair wave agent, hair bleach, hair gel, hair glaze, hair dresser, hair lacquer , hair moisturizer, hair mousse and hair spray may be prepared in one or more formulations.
본 발명의 화장료 조성물은 탈모 방지 또는 발모 촉진이 필요한 피부 부위에 1일 1회 내지 3회 적절한 부피로 도포에 의해 국부 투여될 수 있고 6 주 이상, 12 주 이상 또는 30 주 이상 투여될 수 있다. 투여횟수 및 투여주기는 탈모 증상의 중증도, 희망하는 모발 촉진의 정도에 따라 적절히 조절될 수 있다.The cosmetic composition of the present invention may be administered locally by application in an appropriate volume 1 to 3 times a day to the skin area in need of preventing hair loss or promoting hair growth, and may be administered for 6 weeks or more, 12 weeks or more, or 30 weeks or more. The number of administration and administration cycle may be appropriately adjusted according to the severity of hair loss symptoms and the desired degree of hair promotion.
본 발명의 화장료 조성물은 사용자가 직접 피부에 도포하거나, 모발에 적절히 도포될 수 있도록 하는 장치 또는 기구에 의해 피부에 도포될 수 있다.The cosmetic composition of the present invention may be directly applied to the skin by the user, or may be applied to the skin by a device or apparatus that allows it to be properly applied to the hair.
본 발명의 화장료 조성물은 1종 이상의 탈모 방지 또는 발모 촉진용 식품, 의약품 또는 화장품과 병용될 수 있으며, 모발 이식술과 함께 또는 그 전후로 사용될 수 있다.The cosmetic composition of the present invention may be used in combination with one or more foods, drugs or cosmetics for preventing hair loss or promoting hair growth, and may be used together with or before or after hair transplantation.
또 다른 일 측면에서, 본 발명은 피페로닐산을 포함하는 탈모 방지 또는 발모 촉진용 약학 조성물을 제공한다. 상기 약학 조성물은 의약품 또는 의약외품으로 사용될 수 있다.In another aspect, the present invention provides a pharmaceutical composition for preventing hair loss or promoting hair growth comprising piperonyl acid. The pharmaceutical composition may be used as a pharmaceutical or quasi-drug.
본 발명에서, 약학 조성물은 경구 투여 또는 비경구 투여를 위한 적합하고 다양한 제형이 될 수 있다. 본 발명에서, 경구 투여용 제형은 예를 들어, 정제, 환제, 분말, 산제, 과립, 펠렛, 캡슐, 트로키(troches), 로젠지(lozenge), 현탁액, 에멀젼, 시럽 및 엘릭시르제 등을 들 수 있으나, 이에 한정되지 않는다. 본 발명의 약학 조성물에서, 비경구 투여용 제형은 예를 들어, 주사제, 좌제, 호흡기 흡입제, 에어로졸제, 연고, 액제, 로션제, 패치제, 도포용 분말, 오일, 크림, 겔 등을 들 수 있으나, 이에 한정되는 않는다.In the present invention, the pharmaceutical composition may be in various formulations suitable for oral administration or parenteral administration. In the present invention, formulations for oral administration include, for example, tablets, pills, powders, powders, granules, pellets, capsules, troches, lozenges, suspensions, emulsions, syrups and elixirs. However, the present invention is not limited thereto. In the pharmaceutical composition of the present invention, formulations for parenteral administration include, for example, injections, suppositories, respiratory inhalants, aerosols, ointments, solutions, lotions, patches, powders for application, oils, creams, gels, etc. However, the present invention is not limited thereto.
본 발명에서, 약학 조성물은 목적에 따라 경구 투여하거나 비경구 투여할 수 있다. 본 발명에서, 비경구 투여는 예를 들어, 복강 투여, 직장 투여, 피하 투여, 정맥 투여, 근육 투여, 흉부 투여, 뇌혈관 투여, 경피 투여 및 모발 투여를 들 수 있고, 조성물을 질환 부위에 도포하거나 분무, 흡입하는 것도 들 수 있으나. 이에 한정되는 것은 아니다. 본 발명의 구체적인 구현예에서, 본 발명의 약제학적 조성물은 국부로 도포될 수 있다.In the present invention, the pharmaceutical composition may be administered orally or parenterally, depending on the purpose. In the present invention, parenteral administration includes, for example, intraperitoneal administration, rectal administration, subcutaneous administration, intravenous administration, intramuscular administration, chest administration, cerebrovascular administration, transdermal administration and hair administration, and the composition is applied to the diseased site It can be sprayed, inhaled, or sprayed. The present invention is not limited thereto. In a specific embodiment of the present invention, the pharmaceutical composition of the present invention may be applied topically.
본 발명의 약학 조성물은 약학적으로 유효한 양으로 투여한다. 본 발명에서, 약학적으로 유효한 양은 의학적 치료에 적용 가능한 합리적인 수혜/위험 비율로 질환을 치료하기에 충분한 양을 의미하며, 유효한 양의 수준은 환자의 상태, 체중, 성별, 연령, 건강상태, 질병의 정도, 약물에 대한 민감도, 투여 시간, 투여 경로, 배출 비율, 치료 기간, 동시 사용되는 약물을 포함한 요소 및 기타 의학 분야에 잘 알려진 요소에 따라 결정될 수 있다. 본 발명의 약학 조성물의 투여량은 통상의 기술자에 의해 적절하게 선택될 수 있다.The pharmaceutical composition of the present invention is administered in a pharmaceutically effective amount. In the present invention, a pharmaceutically effective amount means an amount sufficient to treat a disease at a reasonable benefit/risk ratio applicable to medical treatment, and the level of an effective amount is the patient's condition, weight, sex, age, health condition, disease It can be determined according to factors including the degree of drug use, sensitivity to drugs, administration time, administration route, excretion rate, duration of treatment, co-administered drugs, and other factors well known in the medical field. The dosage of the pharmaceutical composition of the present invention may be appropriately selected by those skilled in the art.
본 발명의 약학 조성물의 구체적인 사용양태는 서로 모순되지 않는 이상 상술한 화장료 조성물에서 기재된 것과 동일하게 적용된다.Specific usage aspects of the pharmaceutical composition of the present invention are applied in the same manner as described in the above-described cosmetic composition unless they contradict each other.
또 다른 일 측면에서, 본 발명은 피페로닐산을 포함하는 탈모 방지 또는 발모 촉진용 식품 조성물을 제공한다. 본 발명에서, 식품 조성물은 통상적인 의미에서의 식품 형태일 수 있으며, 예컨대 음료, 드링크제, 분말제, 정제 및 건강기능식품 등일 수 있다.In another aspect, the present invention provides a food composition for preventing hair loss or promoting hair growth comprising piperonyl acid. In the present invention, the food composition may be in the form of a food in a conventional sense, for example, a beverage, a drink, a powder, a tablet, and a health functional food.
일 실시양태에서, 본 발명의 식품 조성물은 건강기능식품일 수 있다. 본 발명에서 건강기능식품은 인체에 유용한 기능성을 가진 원료나 성분을 사용하여, 영양 공급 외에도 생체조절기능이 효율적으로 나타나도록 제조 및 가공한 식품을 의미한다. In one embodiment, the food composition of the present invention may be a dietary supplement. In the present invention, health functional food refers to a food manufactured and processed using raw materials or ingredients having useful functions in the human body to efficiently exhibit bioregulatory functions in addition to nutrition supply.
또 다른 일 측면에서, 본 발명은 피페로닐산을 체외에서 모발 세포에 처리하여 모발 세포의 성장 또는 증식을 촉진하는 방법을 제공한다. 상기 모발 세포는 모유두세포일 수 있고, 구체적으로 안드로겐성 탈모 환자의 모유두 세포일 수 있다(도 2 내지 도 4). 상기 방법에 사용되는 피페로닐산은 10 내지 1,000 μM의 농도로 사용될 수 있으나 이에 제한되지 않는다.In another aspect, the present invention provides a method for promoting the growth or proliferation of hair cells by treating the hair cells with piperonyl acid in vitro. The hair cells may be dermal papilla cells, and specifically may be dermal papilla cells of androgenetic alopecia patients ( FIGS. 2 to 4 ). The piperonyl acid used in the method may be used at a concentration of 10 to 1,000 μM, but is not limited thereto.
본 발명은 또한, 피페로닐산을 유효성분으로 포함하는 모발 세포 배양용 배지 조성물을 제공한다. 상기 모발 세포는 모유두 세포일 수 있고, 구체적으로 안드로겐성 탈모 환자의 모유두 세포일 수 있으며, 피페로닐산은 10 내지 1,000 μM의 농도로 사용될 수 있으나 이에 제한되지 않는다.The present invention also provides a medium composition for culturing hair cells comprising piperonyl acid as an active ingredient. The hair cells may be dermal papilla cells, specifically dermal papilla cells of androgenetic alopecia patients, and piperonyl acid may be used at a concentration of 10 to 1,000 μM, but is not limited thereto.
이하, 본 발명의 구체적인 제조예 및 실시예를 기술한다. 이는 본 발명의 바람직한 일 실시양태를 예시적으로 기재한 것이며, 통상의 기술자는 이를 참고로 하여 본 발명의 청구범위와 그 등가물을 보다 용이하게 이해하고 재현할 수 있을 것이다.Hereinafter, specific preparation examples and examples of the present invention will be described. This is an exemplary description of one preferred embodiment of the present invention, and those skilled in the art will be able to more easily understand and reproduce the claims of the present invention and equivalents thereof with reference to this.
<제조예> 피페로닐산 및 이를 포함하는 조성물의 제조<Preparation Example> Preparation of piperonyl acid and a composition comprising the same
본 발명의 세포 실험에 사용된 피페로닐산은 ㈜시그마알드리치에서 구입하여 사용하였다. 본 발명의 인체적용시험에 적용된 화장료 조성물의 조성 및 조성물 기준 함량은 하기 표 1에 기재된 바와 같으며, 그 형태는 도 1에 표시된 사진과 같다.Piperonyl acid used in the cell experiments of the present invention was purchased from Sigma-Aldrich Co., Ltd. and used. The composition and composition reference content of the cosmetic composition applied to the human application test of the present invention are as shown in Table 1 below, and the form is as shown in the photograph shown in FIG. 1 .
[표 1][Table 1]
<실시예 1> 안드로겐성 탈모 관련 모유두세포의 세포 증식 효과 확인<Example 1> Confirmation of cell proliferation effect of androgenetic hair loss-related dermal papilla cells
실험에 사용된 안드로겐성 탈모 관련 모유두세포는, 남성 안드로겐성 탈모 환자에서 유래된 모유두세포(Dermal Papilla Cell; DPC, passage 1)에 hTERT와 SV40-Tag를 삽입하여 불멸화시킨 세포주로, ㈜에피바이오텍에서 입수하여 사용하였다. 모유두세포의 증식은 MTT tetrazolium을 사용하여 확인하였다. MTT tetrazolium은 세포 내의 미토콘드리아 효소에 의해 MTT formazan으로 환원되며 이 때 노란색이 청자색으로 바뀌게 된다. 많은 세포가 존재할수록 더 강하게 환원되기 때문에 더 강한 청자색이 나타나며, 540nm에서 청자색의 흡광도를 측정하여 살아있는 세포의 농도를 측정한다. 구체적으로, 96 well 세포 배양 plate에 1x104 개의 세포를 분주하고 24시간 배양한다. 이후 무혈청 배지에 50μM의 피페로닐산을 처리한 후 24시간 배양하였다. 이후 MTT 시약을 세포에 두 시간 처리한 후 DMSO를 추가하여 540nM에서 발색을 확인함으로 세포성장을 분석하였다. 음성대조군으로는 용매인 DMSO를 사용하였다.The androgenetic hair loss-related dermal papilla cells used in the experiment are cell lines immortalized by inserting hTERT and SV40-Tag into dermal papilla cells (DPC, passage 1) derived from male androgenetic alopecia patients. It was obtained and used. The proliferation of dermal papilla cells was confirmed using MTT tetrazolium. MTT tetrazolium is reduced to MTT formazan by intracellular mitochondrial enzymes, and at this time, yellow is changed to blue-violet. The more cells there are, the stronger the reduction is, so a stronger blue-violet color appears, and the concentration of living cells is measured by measuring the absorbance of the blue-violet color at 540 nm. Specifically, 1x10 4 cells were dispensed in a 96-well cell culture plate and cultured for 24 hours. Thereafter, the serum-free medium was treated with 50 μM piperonyl acid and cultured for 24 hours. After treating the cells with MTT reagent for two hours, DMSO was added to confirm the color development at 540 nM, and cell growth was analyzed. As a negative control, DMSO as a solvent was used.
그 결과, 피페로닐산을 처리할 경우 안드로겐성 탈모 관련 모유두세포의 세포 증식이 촉진됨을 확인하였다(도 2).As a result, it was confirmed that the cell proliferation of androgenetic alopecia-related dermal papilla cells was promoted when the piperonyl acid was treated (FIG. 2).
또한, 안드로겐성 탈모 관련 모유두세포의 증식에 관여하는 유전자 발현 양상을 살펴보기 위해, 상기 인간 모유두세포를 무혈청 배지에서 24시간동안 배양한 후 25, 50μM의 피페로닐산을 각각 처리하였다. 약물을 처리하고 24시간 후 Cyclin D의 레벨을 Western blotting 방법을 통해 분석하였다. 항체는 Cyclin D의 항체와 각 lane간의 전체 단백질 양을 보정하기 위해 항상 일정하게 발현되는 GAPDH를 이용하였다. 음성대조군으로는 용매인 DMSO를 사용하였다.In addition, in order to examine the gene expression pattern involved in the proliferation of androgenetic alopecia-related dermal papilla cells, the human dermal papilla cells were cultured for 24 hours in a serum-free medium and then treated with 25 and 50 μM piperonyl acid, respectively. After 24 hours of drug treatment, the level of Cyclin D was analyzed by Western blotting. As the antibody, GAPDH, which is always constantly expressed, was used to correct the total amount of protein between the Cyclin D antibody and each lane. As a negative control, DMSO as a solvent was used.
그 결과, 피페로닐산이 처리된 안드로겐성 탈모 관련 모유두세포에서 세포 증식에 관여하는 Cyclin D 단백질의 발현이 대조군 대비 유의하게 상승함을 확인하였다(도 3).As a result, it was confirmed that the expression of Cyclin D protein involved in cell proliferation in androgenetic alopecia-related dermal papilla cells treated with piperonyl acid was significantly increased compared to the control group (FIG. 3).
한편, 피페로닐산 처리 시 안드로겐성 탈모 관련 모유두 세포의 증식 양상을 살펴보기 위해, 상기 인간 모유두세포를 12-well 세포배양 plate에 가득 키우고 yellow tip을 사용하여 세포에 상처를 주었다. 이 후 무혈청 배지에서 피페로닐산 100μM을 처리한 후 24시간, 48시간째 세포성장 촉진 효능을 관찰하였다. 음성대조군으로는 용매인 DMSO를 사용하였다.On the other hand, in order to examine the proliferation pattern of androgenetic alopecia-related dermal papilla cells during piperonyl acid treatment, the human dermal papilla cells were fully grown in a 12-well cell culture plate and a yellow tip was used to injure the cells. Thereafter, the cell growth promoting efficacy was observed at 24 hours and 48 hours after treatment with 100 μM of piperonyl acid in a serum-free medium. As a negative control, DMSO as a solvent was used.
그 결과, 피페로닐산을 처리할 경우 안드로겐성 탈모 관련 모유두세포의 세포 증식이 촉진됨을 재확인하였다(도 4).As a result, it was reconfirmed that the cell proliferation of androgenetic alopecia-related dermal papilla cells was promoted when treated with piperonyl acid (FIG. 4).
<실시예 2> 인체적용시험을 통한 탈모 방지 또는 발모 촉진 효과 확인<Example 2> Confirmation of hair loss prevention or hair growth promotion effect through human application test
탈모는 모발 세포를 구성하는 다양한 종류의 세포가 상호작용함으로써 나타나는 증상이기 때문에, 실시예 1에서 확인한 모유두세포 대상 세포 증식 촉진 효과 외에도, 실제 인체에 적용되었을 경우 피페로닐산이 탈모 방지 또는 발모 촉진 효과가 있는지 여부를 인체적용시험을 통해 확인하였다. Since hair loss is a symptom caused by the interaction of various types of cells constituting hair cells, in addition to the dermal papilla cell target cell proliferation promoting effect confirmed in Example 1, when applied to the human body, piperonylic acid prevents hair loss or promotes hair growth It was confirmed through a human application test.
구체적으로, 안드로겐성 탈모 증상을 나타내는 남성 피험자들(3인 이상)에 대해, 상기 제조예에서 조제한 화장료 조성물(피페로닐산 0.1% 함유 헤어토닉)을 하루 1회 12 주 동안 피부에 도포하였다. 화장료 조성물은 피험자들에게 모발이 부족한 두피 부위에 두피에 물기가 없는 상태에서 2 mL씩 도포되도록 피험자에게 지시되었다.Specifically, for male subjects (3 or more) exhibiting symptoms of androgenetic alopecia, the cosmetic composition (hair tonic containing 0.1% piperonyl acid) prepared in Preparation Example was applied to the skin once a day for 12 weeks. The cosmetic composition was instructed to be applied by 2 mL to the scalp area with insufficient hair to the subjects in a state where the scalp was not wet.
12 주간 인체적용시험 후 전문가 패널이 임상 사진을 평가한 결과, 본 발명의 피페로닐 함유 조성물은 화장품으로 적용 가능한 피부 안전성 및 피부 흡수도를 나타냈다. 또한, 피험자들 모두 전반적으로 모발이 굵고 건강해지고, 모발에 탄력이 생겨 전체적으로 볼륨감이 강화되어 만족감을 나타내었다. As a result of evaluation of clinical pictures by an expert panel after a 12-week human application test, the composition containing piperonil of the present invention showed skin safety and skin absorption that can be applied as cosmetics. In addition, all of the subjects showed a feeling of satisfaction as their hair was generally thick and healthy, and the hair had elasticity, which strengthened the overall sense of volume.
인체적용시험 결과를 정량화하기 위해 안드로겐성 탈모 증상 남성 환자 3인의 0, 6, 12주째 두발 상태(25 mm2당 모발의 수)를 도 6으로 정량화하였으며, 통계적 유의성(p < 0.02)을 갖는 탈모 방지 또는 발모 촉진 효과가 있음을 확인하였다.In order to quantify the results of the human application test, the hair condition (number of hairs per 25 mm 2 ) of 3 male patients with androgenetic alopecia symptoms at
이상을 종합하면, 본 발명에 따른 피페로닐산 포함 화장료 조성물은 탈모의 방지 또는 발모 촉진, 구체적으로 모발 건강 개선 및 안드로겐성 탈모 증상 완화에 유용하게 활용될 수 있음을 알 수 있다.Summarizing the above, it can be seen that the cosmetic composition containing piperonyl acid according to the present invention can be usefully used to prevent hair loss or promote hair growth, specifically, to improve hair health and alleviate androgenic alopecia symptoms.
Claims (11)
(i) 모발 굵기 증가, 모발 탄력 강화, 모발 볼륨감 강화 및 모발 수 증가로 구성된 군에서 선택된 1종 이상의 모발 건강 개선 효과;
(ii) 안드로겐성 탈모(androgenic alopecia) 증상 완화 효과; 및
(iii) 모유두(dermal papilla) 세포의 증식 촉진 효과를 나타내는 것을 특징으로 하는
탈모 방지 또는 발모 촉진용 화장료 조성물.
[화학식 1]
(i) one or more hair health improvement effects selected from the group consisting of increasing hair thickness, strengthening hair elasticity, enhancing hair volume, and increasing the number of hairs;
(ii) alleviating androgenic alopecia symptoms; and
(iii) characterized in that it exhibits a proliferation promoting effect of dermal papilla cells
A cosmetic composition for preventing hair loss or promoting hair growth.
[Formula 1]
(i) 모발 굵기 증가, 모발 탄력 강화, 모발 볼륨감 강화 및 모발 수 증가로 구성된 군에서 선택된 1종 이상의 모발 건강 개선 효과;
(ii) 안드로겐성 탈모(androgenic alopecia) 증상 완화 효과; 및
(iii) 모유두(dermal papilla) 세포의 증식 촉진 효과를 나타내는 것을 특징으로 하는
탈모 방지 또는 발모 촉진용 약학 조성물.Piperonylic acid is included in an amount of 0.01% to 5% by weight based on the composition,
(i) one or more hair health improvement effects selected from the group consisting of increasing hair thickness, strengthening hair elasticity, enhancing hair volume, and increasing the number of hairs;
(ii) alleviating androgenic alopecia symptoms; and
(iii) characterized in that it exhibits a proliferation promoting effect of dermal papilla cells
A pharmaceutical composition for preventing hair loss or promoting hair growth.
(i) 모발 굵기 증가, 모발 탄력 강화, 모발 볼륨감 강화 및 모발 수 증가로 구성된 군에서 선택된 1종 이상의 모발 건강 개선 효과;
(ii) 안드로겐성 탈모(androgenic alopecia) 증상 완화 효과; 및
(iii) 모유두(dermal papilla) 세포의 증식 촉진 효과를 나타내는 것을 특징으로 하는
탈모 방지 또는 발모 촉진용 식품 조성물.Piperonylic acid is included in an amount of 0.01% to 5% by weight based on the composition,
(i) one or more hair health improvement effects selected from the group consisting of increasing hair thickness, strengthening hair elasticity, enhancing hair volume, and increasing the number of hairs;
(ii) alleviating androgenic alopecia symptoms; and
(iii) characterized in that it exhibits a proliferation promoting effect of dermal papilla cells
Food composition for preventing hair loss or promoting hair growth.
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020210164105A KR102394488B1 (en) | 2021-11-25 | 2021-11-25 | Composition Comprising Piperonylic Acid for Hair Loss Prevention or Hair Growth Promotion |
| CN202280013852.7A CN116940332A (en) | 2021-11-25 | 2022-10-28 | Composition for preventing hair loss or promoting hair growth comprising piperic acid |
| PCT/KR2022/016654 WO2023096186A1 (en) | 2021-11-25 | 2022-10-28 | Composition comprising piperonylic acid for hair-loss prevention or hair-growth promotion |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020210164105A KR102394488B1 (en) | 2021-11-25 | 2021-11-25 | Composition Comprising Piperonylic Acid for Hair Loss Prevention or Hair Growth Promotion |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR102394488B1 true KR102394488B1 (en) | 2022-05-04 |
Family
ID=81584176
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020210164105A KR102394488B1 (en) | 2021-11-25 | 2021-11-25 | Composition Comprising Piperonylic Acid for Hair Loss Prevention or Hair Growth Promotion |
Country Status (3)
| Country | Link |
|---|---|
| KR (1) | KR102394488B1 (en) |
| CN (1) | CN116940332A (en) |
| WO (1) | WO2023096186A1 (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101859421B1 (en) * | 2017-01-31 | 2018-05-21 | 주식회사 케라메딕스 | Injectable composition for prevention of depilation or improvement of hair growth |
| KR20190014340A (en) * | 2017-08-02 | 2019-02-12 | 포항공과대학교 산학협력단 | An anti-aging or skin regenerating composition comprising piperonylic acid as an active ingredient |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2879443B1 (en) * | 2004-12-21 | 2007-07-13 | Jean Noel Thorel | USE OF A COMPLEX NUTRIENT BASE IN THE COSMETIC DOMAIN, IN PARTICULAR CAPILLARY |
| US9186642B2 (en) * | 2010-04-28 | 2015-11-17 | The Procter & Gamble Company | Delivery particle |
| KR102300364B1 (en) * | 2015-03-31 | 2021-09-10 | (주)아모레퍼시픽 | Composition for promoting hair growth and/or restoration containing psoralidin |
-
2021
- 2021-11-25 KR KR1020210164105A patent/KR102394488B1/en active IP Right Grant
-
2022
- 2022-10-28 CN CN202280013852.7A patent/CN116940332A/en active Pending
- 2022-10-28 WO PCT/KR2022/016654 patent/WO2023096186A1/en active Application Filing
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101859421B1 (en) * | 2017-01-31 | 2018-05-21 | 주식회사 케라메딕스 | Injectable composition for prevention of depilation or improvement of hair growth |
| KR20190014340A (en) * | 2017-08-02 | 2019-02-12 | 포항공과대학교 산학협력단 | An anti-aging or skin regenerating composition comprising piperonylic acid as an active ingredient |
Also Published As
| Publication number | Publication date |
|---|---|
| CN116940332A (en) | 2023-10-24 |
| WO2023096186A1 (en) | 2023-06-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20120114689A1 (en) | Nicotinamide compositions for treatment of skin diseases and disorders | |
| CN107530258B (en) | Composition for promoting hair growth or hair restoration and for anti-inflammation | |
| TW201841618A (en) | Composition for treating skin pigmentation and related methods | |
| CN110693773A (en) | Composition for preventing alopecia or promoting hair growth | |
| KR101792402B1 (en) | Hair growth stimulants comprising nicotinic acid adenine dinucleotide phosphate and its derivatives | |
| KR102115666B1 (en) | Composition comprising nonanal for preventing hair loss or stimulating hair growth | |
| KR101935492B1 (en) | Composition comprising yarayara for preventing hair loss or stimulating hair growth | |
| KR102394488B1 (en) | Composition Comprising Piperonylic Acid for Hair Loss Prevention or Hair Growth Promotion | |
| KR101256588B1 (en) | Composition including beta-carboline alkaloid for stimulating melanin production | |
| KR102472978B1 (en) | Composition for improving skin | |
| JP2023535534A (en) | Gray hair control composition and use thereof | |
| CN107530253B (en) | Composition containing psoralen for promoting hair growth and/or hair growth | |
| KR20170038321A (en) | Composition for improving a scalp condition and/or promoting hair growth and/or restoration containing tectorigenin | |
| CN112004536A (en) | Composition for preventing or treating alopecia | |
| EP4344696A1 (en) | Functional composition for alopecia comprising centipeda minima-derived extract | |
| KR101957845B1 (en) | Composition for improving condition of hair and scalp containing extract of soybean root | |
| JP6787754B2 (en) | Melanin decomposition accelerator | |
| KR20230094217A (en) | Composition for preventing hair loss and promoting hair growth comprising Luteolin-7-glucoside | |
| KR101984276B1 (en) | A body hair growth inhibition composition comprising berberine hydrochloride as an effective ingredient | |
| KR20230094216A (en) | Composition for preventing hair loss and promoting hair growth comprising Genkwanin | |
| KR102349947B1 (en) | Composition for improving skin | |
| KR20210118272A (en) | A composition comprising kakkalide | |
| KR102351478B1 (en) | Composition for improving skin | |
| KR20230076422A (en) | Composition for treating or preventing alopecia comprising decursin | |
| CN115887475A (en) | Production and/or activity promoter for silk fibroin and/or VEGF-C, and skin external preparation using the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant |